Taken together, our study explored the molecular mechanism between RA and DLBCL for the first time and identified that LGALS2 is a potential therapeutic target and an immune-related biomarker for patients with RA and DLBCL. Here, LGALS2 is linked to diffuse large B-cell lymphoma.